(Q38141236)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Chaim Charytan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

24 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

131-138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

FGF23 and PTH--double agents at the heart of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Renal bone disease 1990: an unmet challenge for the nephrologist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

21 January 2018

Cinacalcet hydrochloride

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Consistent control of mineral and bone disorder in incident hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects of phosphate binders in moderate CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Vascular calcification in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Mechanisms of vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Change in coronary artery calcification score due to cinacalcet hydrochloride administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

FGF-23/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Latest findings in phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Update on fibroblast growth factor 23 in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Klotho deficiency causes vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Effects of treatment of renal osteodystrophy on bone histology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.832319

10.3109/0886022X.2013.832319

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24060145%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference